Oncology Pharma Inc. (OTCMKTS:ONPH) Sees Significant Increase in Short Interest
Oncology Pharma Inc. (OTCMKTS:ONPH) Sees Significant Increase in Short Interest
Oncology Pharma Inc. (OTCMKTS:ONPH – Get Rating) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 27,300 shares, a growth of 45.2% from the March 15th total of 18,800 shares. Based on an average trading volume of 300,600 shares, the short-interest ratio is currently 0.1 days.
Oncology Pharma Price Performance
ONPH stock remained flat at $0.19 during trading on Tuesday. The company had a trading volume of 66,849 shares, compared to its average volume of 67,927. The stock has a 50 day moving average price of $0.28 and a 200-day moving average price of $0.47. Oncology Pharma has a 1-year low of $0.16 and a 1-year high of $3.60.
Get Oncology Pharma alerts:About Oncology Pharma
(Get Rating)
Oncology Pharma, Inc engages in the development, manufacture and commercialization of therapeutics. The company was founded by Marcel van Heesewijk on March 26, 1993 and is headquartered in San Francisco, CA.
See Also
- Get a free copy of the StockNews.com research report on Oncology Pharma (ONPH)
- Gamida Cell Stock Jumps Over 100% on FDA Approval
- Insiders Buy EasyJet, Regularly And Repeatedly
- Bank of America Beats Earnings, Renews Investor Upside Potential
- The Analysts See A Bright Future For Sunrun
- J.B. Hunt: Economic Contraction And A Buying Opportunity
Receive News & Ratings for Oncology Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncology Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
Oncology Pharma Inc. (OTCMKTS:ONPH – Get Rating) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 27,300 shares, a growth of 45.2% from the March 15th total of 18,800 shares. Based on an average trading volume of 300,600 shares, the short-interest ratio is currently 0.1 days.
Oncology Pharma Inc.（OTCMKTS: ONPH — 獲取評級）是3月份空頭利息大幅增長的目標。截至3月31日，空頭利息總額爲27,300股，較3月15日的18,800股增長了45.2％。根據300,600股的平均交易量，目前的空頭利率爲0.1天。
Oncology Pharma Price Performance
腫瘤製藥價格表現
ONPH stock remained flat at $0.19 during trading on Tuesday. The company had a trading volume of 66,849 shares, compared to its average volume of 67,927. The stock has a 50 day moving average price of $0.28 and a 200-day moving average price of $0.47. Oncology Pharma has a 1-year low of $0.16 and a 1-year high of $3.60.
在週二的交易中，ONPH股價持平至0.19美元。該公司的交易量爲66,849股，而平均成交量爲67,927股。該股的50天移動平均價格爲0.28美元，200天移動平均線價格爲0.47美元。腫瘤製藥的1年低點爲0.16美元，爲1年高點3.60美元。
About Oncology Pharma
關於腫瘤製藥
(Get Rating)
（獲取評級）
Oncology Pharma, Inc engages in the development, manufacture and commercialization of therapeutics. The company was founded by Marcel van Heesewijk on March 26, 1993 and is headquartered in San Francisco, CA.
Oncology Pharma, Inc從事療法的開發、製造和商業化。該公司由馬塞爾·範·海瑟維克於1993年3月26日創立，總部位於加利福尼亞州舊金山。
See Also
另請參閱
- Get a free copy of the StockNews.com research report on Oncology Pharma (ONPH)
- Gamida Cell Stock Jumps Over 100% on FDA Approval
- Insiders Buy EasyJet, Regularly And Repeatedly
- Bank of America Beats Earnings, Renews Investor Upside Potential
- The Analysts See A Bright Future For Sunrun
- J.B. Hunt: Economic Contraction And A Buying Opportunity
- 免費獲取 StockNews.com 關於腫瘤製藥 (ONPH) 的研究報告的副本
- 經美國食品藥品管理局批准，Gamida Cell的股票上漲了100％以上
- 內部人士定期反覆收購易捷航空
- 美國銀行超過收益，重新激發了投資者的上行潛力
- 分析師認爲Sunrun的前景光明
- J.B. Hunt：經濟收縮和買入機會
Receive News & Ratings for Oncology Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncology Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
接收腫瘤製藥日報的新聞和收視率 -在下面輸入您的電子郵件地址，以通過Marketbeat.com的免費每日電子郵件時事通訊接收Oncology Pharma及相關公司最新新聞和分析師評級的簡明每日摘要。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧